Literature DB >> 12098063

Lorazepam for seizure prophylaxis during high-dose busulfan administration.

K W Chan1, C A Mullen, L L Worth, M Choroszy, S Koontz, H Tran, J Slopis.   

Abstract

Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis. A number of adverse effects have been associated with DPH and it may also interfere with BU metabolism. We used lorazepam (median dose 0.022 mg/kg) i.v. or p.o. before each dose and for 24 h after the last dose of BU as seizure prophylaxis to 29 children undergoing hematopoietic stem cell transplantation. The regimen was well tolerated and drowsiness was the only significant side-effect. Twelve patients were able to receive the entire prophylaxis by mouth. No seizure developed during and within 48 h of BU. Concomitant pharmacokinetic studies showed no alternation of the absorption and clearance of BU during lorazepam administration. Lorazepam can be used as an alternative for seizure prophylaxis during high-dose BU treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12098063     DOI: 10.1038/sj.bmt.1703593

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

Review 1.  Neurologic complications of cancer and its treatment.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

2.  Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Authors:  Eucario Leon-Rodriguez; Monica M Rivera-Franco
Journal:  Int J Hematol       Date:  2016-10-08       Impact factor: 2.490

Review 3.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 4.  Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment.

Authors:  Gagandeep Singh; Jeremy H Rees; Josemir W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

Review 5.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

Review 6.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

7.  Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan.

Authors:  Maria Sacramento Diaz-Carrasco; Raquel Olmos; Miguel Blanquer; Javier Velasco; Andrés Sánchez-Salinas; José María Moraleda
Journal:  Int J Clin Pharm       Date:  2013-04-11

8.  Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation.

Authors:  M Hadjibabaie; S Rahimian; Z Jahangard-Rafsanjani; M Amini; K Alimoghaddam; M Iravani; A Ghavamzadeh; S Sadrai
Journal:  Daru       Date:  2011       Impact factor: 3.117

Review 9.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.